Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy

作者：Tao Zhang, Mu Wei, Cheng‐Gong Liao, Yan Hou, Jie Song, Wen Hu, Yun Wang, Dongxu Chen, Yu Chen, Linna Liu, Lili Liu · 发表于：Cancer Chemotherapy and Pharmacology · 年份：2024 · DOI：10.1007/s00280-024-04727-8 · 被引用次数：7 · 研究领域：Intraperitoneal and Appendiceal Malignancies、Occupational and environmental lung diseases、Chemotherapy-induced organ toxicity mitigation

To compare the pharmacokinetics and adverse effects of cisplatin administered via intravenous infusion for systemic chemotherapy (SC) versus injection into the perfusate during hyperthermic intrathoracic chemotherapy (HITHOC) or hyperthermic intraperitoneal chemotherapy (HIPEC). Total 60 patients who received SC, HITHOC, or HIPEC in the Department of Oncology, Tangdu Hospital, were enrolled into this study. After administering same dose of cisplatin (40 mg) via either intravenous infusion (SC group) or injection into the perfusate during the HITHOC or HIPEC procedure, concentration of cisplatin in the plasma as well as in the hyperthermic perfusate at various time points was quantified by HPLC analysis. The area under the plasma or perfusate concentration–time curve over the last 24h dosing interval (AUC 0–24h ), mean residence time over the 24 h (MRT 0–24h ), terminal elimination half-life (t 1/2z ), time to peak concentration (T max ), apparent clearance (Clz/F), and peak concentration (C max ) in the perfusate and plasma were compared. In the perfusate, the AUC 0–24h (64.32 ± 27.12 µg/mL·h) and C max (21.62 ± 5.88 µg/mL) were significantly higher in the HITHOC group compared to that in the HIPEC group (31.68 ± 13.29 µg/mL·h and 16.96 ± 5.54 µg/mL, respectively, p ≤ 0.01). In contrast, MRT 0–∞ , t 1/2z , and Clz/F were significantly lower in the HITHOC group compared to that in the HIPEC group ( p < 0.01). In the plasma, average AUC 0–24h and C max of the HITHOC group were ...